Although the expression levels of BCL2L11 were higher in breast cancer tissues compared to normal breast tissues (p < 0.001, Supplementary Figure S1B), patients with higher BCL2L11 expression within the breast cancer cohort exhibited better RFS and OS compared to those with lower BCL2L11 expression (log-rank p = 0.0016 and 0.013, respectively; Supplementary Figures S1E, H). Here, BCL2L11 is linked to breast carcinoma.